Abstracts tagged "randomized trials and spondylarthritis"

Abstract Number: 2876 • 2015 ACR/ARHP Annual Meeting
Baseline Demographic and Disease Characteristics Associated with Response to Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
Maxime Dougados¹, Gina Bergman², Walter Maksymowych³, Sean P. Curtis², Susan Huyck², Anjela Tzontcheva² and Joachim Sieper⁴, ¹Paris-Descartes University, Paris, France, ²Merck & Co., Inc., Kenilworth, NJ, ³University of Alberta, Edmonton, AB, Canada, ⁴University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: Subgroup analyses can be used to investigate the size and direction of treatment effects across a range of demographic and disease characteristics. The purpose…
Abstract Number: 1546 • 2013 ACR/ARHP Annual Meeting
Patient-Reported Outcomes of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial
Maxime Dougados¹, Wen-Chan Tsai², Diego Luis Saaibi³, Randi Bonin⁴, Jack Bukowski⁵, Ronald Pedersen⁶, Bonnie Vlahos⁷ and Sameer Kotak⁸, ¹Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ²Chung-Ho Memorial Hospital, Kaohsiung, 807, Taiwan, ³MEDICITY S.A.S, Bucaramanga, Santander 681001, Colombia, ⁴Pfizer Inc, Collegeville, PA, ⁵Department of Specialty Care, Pfizer Inc, Collegeville, PA, ⁶Specialty Care, Pfizer Inc, Collegeville, PA, ⁷Department of Specialty Care, Pfizer Inc., Collegeville, PA, ⁸Specialty Care, Pfizer Inc., New York, NY
Background/Purpose: Limited data are available on the efficacy of anti-TNF agents in non-radiographic axial spondyloarthritis (nr-axSpA). This analysis compares the impact of etanercept (ETN) vs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].